Medical education in pharmacogenomics-results from a survey on pharmacogenetic knowledge in healthcare professionals within the European pharmacogenomics clinical implementation project Ubiquitous Pharmacogenomics (U-PGx)

Personalised Therapeutic

SU(4) Chiral Quark Model with Configuration Mixing

Chiral quark model with configuration mixing and broken SU(3)\times U(1) symmetry has been extended to include the contribution from c\bar c fluctuations by considering broken SU(4) instead of SU(3). The implications of such a model have been studied for quark flavor and spin distribution functions corresponding to E866 and the NMC data. The predicted parameters regarding the charm spin distribution functions, for example, \Delta c, \frac{\Delta c}{{\Delta \Sigma}}, \frac{\Delta c}{c} as well as the charm quark distribution functions, for example, \bar c, \frac{2\bar c}{(\bar u+\bar d)}, \frac{2 \bar c}{(u+d)} and \frac{(c+ \bar c)}{\sum (q+\bar q)} are in agreement with other similar calculations. Specifically, we find \Delta c=-0.009, \frac{\Delta c}{{\Delta \Sigma}}=-0.02, \bar c=0.03 and \frac{(c+ \bar c)}{\sum (q+\bar q)}=0.02 for the \chiQM parameters a=0.1, \alpha=0.4, \beta=0.7, \zeta_{E866}=-1-2 \beta, \zeta_{NMC}=-2-2 \beta and \gamma=0.3, the latter appears due to the extension of SU(3) to SU(4).Comment: 10 RevTeX pages. Accepted for publication in Phys. Rev.

Improved Measurement of the dˉ/uˉ\bar d / \bar u Asymmetry in the Nucleon Sea

Measurements of the ratio of Drell-Yan yields from an 800 \rm{GeV/c} proton beam incident on liquid hydrogen and deuterium targets are reported. Approximately 360,000 Drell-Yan muon pairs remained after all cuts on the data. From these data, the ratio of anti-down ($\bar{d}$) to anti-up ($\bar{u}$) quark distributions in the proton sea is determined over a wide range in Bjorken-$x$. These results confirm previous measurements by E866 and extend them to lower $x$. From these data, $(\bar{d}-\bar{u})$ and $\int(\bar{d}-\bar{u})dx$ are evaluated for $0.015<x<0.35$. These results are compared with parameterizations of various parton distribution functions, models and experimental results from NA51, NMC, and HERMES.Comment: 17 pages, 15 figure

Risk profiles and one-year outcomes of patients with newly diagnosed atrial fibrillation in India: Insights from the GARFIELD-AF Registry.

BACKGROUND: The Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF) is an ongoing prospective noninterventional registry, which is providing important information on the baseline characteristics, treatment patterns, and 1-year outcomes in patients with newly diagnosed non-valvular atrial fibrillation (NVAF). This report describes data from Indian patients recruited in this registry. METHODS AND RESULTS: A total of 52,014 patients with newly diagnosed AF were enrolled globally; of these, 1388 patients were recruited from 26 sites within India (2012-2016). In India, the mean age was 65.8 years at diagnosis of NVAF. Hypertension was the most prevalent risk factor for AF, present in 68.5% of patients from India and in 76.3% of patients globally (P < 0.001). Diabetes and coronary artery disease (CAD) were prevalent in 36.2% and 28.1% of patients as compared with global prevalence of 22.2% and 21.6%, respectively (P < 0.001 for both). Antiplatelet therapy was the most common antithrombotic treatment in India. With increasing stroke risk, however, patients were more likely to receive oral anticoagulant therapy [mainly vitamin K antagonist (VKA)], but average international normalized ratio (INR) was lower among Indian patients [median INR value 1.6 (interquartile range {IQR}: 1.3-2.3) versus 2.3 (IQR 1.8-2.8) (P < 0.001)]. Compared with other countries, patients from India had markedly higher rates of all-cause mortality [7.68 per 100 person-years (95% confidence interval 6.32-9.35) vs 4.34 (4.16-4.53), P < 0.0001], while rates of stroke/systemic embolism and major bleeding were lower after 1 year of follow-up. CONCLUSION: Compared to previously published registries from India, the GARFIELD-AF registry describes clinical profiles and outcomes in Indian patients with AF of a different etiology. The registry data show that compared to the rest of the world, Indian AF patients are younger in age and have more diabetes and CAD. Patients with a higher stroke risk are more likely to receive anticoagulation therapy with VKA but are underdosed compared with the global average in the GARFIELD-AF. CLINICAL TRIAL REGISTRATION-URL: http://www.clinicaltrials.gov. Unique identifier: NCT01090362

The LHCb upgrade I

The LHCb upgrade represents a major change of the experiment. The detectors have been almost completely renewed to allow running at an instantaneous luminosity five times larger than that of the previous running periods. Readout of all detectors into an all-software trigger is central to the new design, facilitating the reconstruction of events at the maximum LHC interaction rate, and their selection in real time. The experiment's tracking system has been completely upgraded with a new pixel vertex detector, a silicon tracker upstream of the dipole magnet and three scintillating fibre tracking stations downstream of the magnet. The whole photon detection system of the RICH detectors has been renewed and the readout electronics of the calorimeter and muon systems have been fully overhauled. The first stage of the all-software trigger is implemented on a GPU farm. The output of the trigger provides a combination of totally reconstructed physics objects, such as tracks and vertices, ready for final analysis, and of entire events which need further offline reprocessing. This scheme required a complete revision of the computing model and rewriting of the experiment's software

Targeting of renal cell carcinoma with Iodine-131-labeled chimeric monoclonal antibody G250

Contains fulltext : 24971___.PDF (publisher's version ) (Open Access